When monitoring the PERK-eIF2α signal pathway in esophageal cancer cells after CUDC-907 treatment, we did not detect significant changes of p-PERK and p-eIF2α, suggesting the PERK signal cascade was inactivated. This evidence concerns the gene EIF2AK3 and esophageal cancer.